| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.12 | 0.002 |
| mRNA | (5Z)-7-Oxozeaenol | GDSC1000 | pan-cancer | AAC | 0.1 | 0.002 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | 0.14 | 0.002 |
| mRNA | BMS-270394 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | TAK-715 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.002 |
| mRNA | BIX02189 | GDSC1000 | pan-cancer | AAC | 0.099 | 0.003 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | 0.15 | 0.003 |
| mRNA | Genentech Cpd 10 | GDSC1000 | pan-cancer | AAC | 0.095 | 0.003 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | 0.16 | 0.004 |